- J-STAGE home
- /
- JOURNAL OF JAPAN SOCIETY FOR H ...
- /
- Volume 13 (2003) Issue 3
- /
- Article overview
[title in Japanese]
JOURNAL
FREE ACCESS
2003 Volume 13 Issue 3 Pages 113-123
Details
- Published: March 30, 2004 Received: - Available on J-STAGE: February 25, 2011 Accepted: - Advance online publication: - Revised: -
-
Correction information
Date of correction: February 25, 2011 Reason for correction: - Correction: CITATION Details: Wrong : 1) Vogl SE, Schoenfeld DA, Kaplan BH et al : A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56 : 432-442, 1985.
2) Clavel M, Cognetti F, Dodion P et al: Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer 60: 1173-1177, 1987.
3) Forastiere AA, Metch b, Schuller DE et al : Randomized comparison of cisplarin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck : a Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992.
4) Jacobs C, Lyman G, Velez-Garcia E et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992.
5) Clavel M, Vermorken JB, Cognetti F et al : Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinooma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521-526, 1994.
6) Murphy B, Li Y, Cella D et al: Phase III study comparing cisplatin / 5-fluorouracil versus cisplatin / paclitaxel in metastatic / recurrent head and neck. ASCO 20:224a, 2001. (abstr #894)
7) Paccagnella A, Pappagallo GL, Segati R et al: Response and toxicity and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck. Am J Clin Oncol 13:194-198,1990,
9) Stell PM:Time to recurrence of squamous cell carcinoma of the head and neck. Head Neck 13 : 277-281, 1991.
10) Pivot X, Niyikiza C, Poissonnet G et al: Clinical prognostic factor for patients with recurrent head and neck cancer:implications for randomized trials. Oncology 61: 197-204, 2000.
11) Recondo G, Armand JP, Tellez-Bernal E et al:Recurrent and/or metastatic head and neck squamous cell carcinoma:aclinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 101:494-501, 1991.
12) Beck A, Etienne MC, Cheradame S et al:A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fruorouracil. Eur J Cancer 30A: 1517-1522, 1994.
13) Etienne MC, Cheradame S, Fischel JL et al Response to fluorouracil therapy in cancer patients:the role of tumoral dihydropy-rimidine dehydrogenase activity. J Clin Oncol 13 : 1663-1670, 1995.
14) Kawasaki G, Yoshitomi I Yamamoto S et al:Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94: 717-723, 2002.
15) Forastiere AA, Takasugi BJ, Baker SR et al:High dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 19: 155-158, 1987.
16) Robbins KT, Stoniolo AM, Kerber C et al Phase I study of highly selective supradose cisplatin infusion for advanced head and neck cancer. J CIin Oncol 12 : 2113-2120, 1994.
17) Bobbins KT, Kumar P, Wong FSH et al: Targeted chemoradiotherapy for advanced head and neck cancer:analysis of 213 patients. Head Neck 22: 687-693, 2000.
18) Kumar P, Robins KT, Harris J et al: Intraarterial cisplatin and radiation therapy is feasible in a multi-institutional setting for the treatment of stage IV-T4 head and neck squamous cell carcinoma: lnitial results of Radiation Therapy Oncology Group(RTOG)trial 9615. ASCO 20:230a, 2001. (abstr # 918)
19) Schrijvers D, Johnson J, Jiminez U et al; Phase III trial of modulation of cisplatin/ fluorouracil chemotherapy by interferon alfa- 2b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 16: 1054-1059, 1998.
20) Colevas AD, Amein PC, Gomolin H et al : A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Cancer 92: 326-331, 2001.
21) Clark JR, Busse PM, Norris CM et al: Induction chemotherapy with cisplatin, fluorouracil, and high dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 15: 3100-3110, 1997.
22) The Meta-analysis Group in Cancer : Toxicity of fluorouracil in patients with advanced colorectal cancer : effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537-3541, 1998.
23) Gonzalez-Larriba JL, Carbonero IG, Valera JS et al: Neoadjuvant therapy with cispla-tin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer. Oncology 11(Suppl 10) : 90-97, 1997.
24) Gebbia V, RossoA, Gebbia N et al : High dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck. J Cancer Res Clin Oncol 118: 58-62, 1992.
25) Riva C, Lavielle JP, Schmerber S et al: Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer : a pharmacokinetic and clinical survey. Int J Oncol 17 : 543-549, 2000.
26) Wang HM, Wang CS, Chen JS et al: Cisplatin, tegafur, and leucovorin. A modarately effective minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 94: 2989-2995, 2002.
27) Grem JL, McAtee n, Balis F et al : A phase II study of continuous infusion 5-fluorou-racil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 72 : 663-668. 1993.
28) Hansen RM, Ryan L, Anderson T et al : Phase III of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88: 668-674, 1996.
29) Shirasaka T, Yamamitsu S, Tsuji A et al: Conceptional changes in cancer chemotherapy : from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 18 : 315-329, 2000.
30) Kohno N, Kitahara S, Tamura E et al: The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. Jpn J Cancer Chemother 27 suppl II: 592-599. 2000.
32) Nakata B, Mitachi Y, Tsuji A et al : Combination phase I trial of novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer. Clin Cancer Res 10:1664-1669, 2004.
33) Lokich J, Bothe A Fine N et al: Phase Istudy of protracted venous infusion of 5-fluorouracil. Cancer 48: 2565-2568, 1981.
34) Lokich JJ, Zipoli TE : Phase I study of protracted infusion of cisplatin. Cancer Drug Deliv 1: 247-250, 1984.
Right : 1) Vogl SE, Schoenfeld DA, Kaplan BH et al : A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56 : 432-442, 1985.
2) Clavel M, Cognetti F, Dodion P et al: Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer 60: 1173-1177, 1987.
3) Forastiere AA, Metch b, Schuller DE et al : Randomized comparison of cisplarin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck : a Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992.
4) Jacobs C, Lyman G, Velez-Garcia E et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992.
5) Clavel M, Vermorken JB, Cognetti F et al : Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinooma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521-526, 1994.
6) Murphy B, Li Y, Cella D et al: Phase III study comparing cisplatin / 5-fluorouracil versus cisplatin / paclitaxel in metastatic / recurrent head and neck. ASCO 20:224a, 2001. (abstr #894)
7) Paccagnella A, Pappagallo GL, Segati R et al: Response and toxicity and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck. Am J Clin Oncol 13:194-198,1990,
9) Stell PM:Time to recurrence of squamous cell carcinoma of the head and neck. Head Neck 13 : 277-281, 1991.
10) Pivot X, Niyikiza C, Poissonnet G et al: Clinical prognostic factor for patients with recurrent head and neck cancer:implications for randomized trials. Oncology 61: 197-204, 2000.
11) Recondo G, Armand JP, Tellez-Bernal E et al:Recurrent and/or metastatic head and neck squamous cell carcinoma:aclinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 101:494-501, 1991.
12) Beck A, Etienne MC, Cheradame S et al:A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fruorouracil. Eur J Cancer 30A: 1517-1522, 1994.
13) Etienne MC, Cheradame S, Fischel JL et al Response to fluorouracil therapy in cancer patients:the role of tumoral dihydropy-rimidine dehydrogenase activity. J Clin Oncol 13 : 1663-1670, 1995.
14) Kawasaki G, Yoshitomi I Yamamoto S et al:Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94: 717-723, 2002.
15) Forastiere AA, Takasugi BJ, Baker SR et al:High dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 19: 155-158, 1987.
16) Robbins KT, Stoniolo AM, Kerber C et al Phase I study of highly selective supradose cisplatin infusion for advanced head and neck cancer. J CIin Oncol 12 : 2113-2120, 1994.
17) Bobbins KT, Kumar P, Wong FSH et al: Targeted chemoradiotherapy for advanced head and neck cancer:analysis of 213 patients. Head Neck 22: 687-693, 2000.
18) Kumar P, Robins KT, Harris J et al: Intraarterial cisplatin and radiation therapy is feasible in a multi-institutional setting for the treatment of stage IV-T4 head and neck squamous cell carcinoma: lnitial results of Radiation Therapy Oncology Group(RTOG)trial 9615. ASCO 20:230a, 2001. (abstr # 918)
19) Schrijvers D, Johnson J, Jiminez U et al; Phase III trial of modulation of cisplatin/ fluorouracil chemotherapy by interferon alfa- 2b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 16: 1054-1059, 1998.
20) Colevas AD, Amein PC, Gomolin H et al : A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Cancer 92: 326-331, 2001.
21) Clark JR, Busse PM, Norris CM et al: Induction chemotherapy with cisplatin, fluorouracil, and high dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 15: 3100-3110, 1997.
22) The Meta-analysis Group in Cancer : Toxicity of fluorouracil in patients with advanced colorectal cancer : effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537-3541, 1998.
23) Gonzalez-Larriba JL, Carbonero IG, Valera JS et al: Neoadjuvant therapy with cispla-tin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer. Oncology 11(Suppl 10) : 90-97, 1997.
24) Gebbia V, RossoA, Gebbia N et al : High dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck. J Cancer Res Clin Oncol 118: 58-62, 1992.
25) Riva C, Lavielle JP, Schmerber S et al: Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer : a pharmacokinetic and clinical survey. Int J Oncol 17 : 543-549, 2000.
26) Wang HM, Wang CS, Chen JS et al: Cisplatin, tegafur, and leucovorin. A modarately effective minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 94: 2989-2995, 2002.
27) Grem JL, McAtee n, Balis F et al : A phase II study of continuous infusion 5-fluorou-racil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 72 : 663-668. 1993.
28) Hansen RM, Ryan L, Anderson T et al : Phase III of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88: 668-674, 1996.
29) Shirasaka T, Yamamitsu S, Tsuji A et al: Conceptional changes in cancer chemotherapy : from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 18 : 315-329, 2000.
30) Kohno N, Kitahara S, Tamura E et al: The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. Jpn J Cancer Chemother 27 suppl II: 592-599. 2000.
32) Nakata B, Mitachi Y, Tsuji A et al : Combination phase I trial of novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer. Clin Cancer Res 10:1664-1669, 2004.
33) Lokich J, Bothe A Fine N et al: Phase Istudy of protracted venous infusion of 5-fluorouracil. Cancer 48: 2565-2568, 1981.
34) Lokich JJ, Zipoli TE : Phase I study of protracted infusion of cisplatin. Cancer Drug Deliv 1: 247-250, 1984.
Download PDF (1574K)
Download citation
RIS
BIB TEX
Text
How to download citation
Contact us
(compatible with EndNote, Reference Manager, ProCite, RefWorks)
(compatible with BibDesk, LaTeX)
